1818TiPMulticentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. (23rd October 2018) - Pagano, M; Zanelli, F; Gnoni, R; Bonelli, C; Tiseo, M; Boni, L; Ceresoli, G L; Zucali, P A; Grosso, F; Pasello, G; Cappuzzo, F; Pinto, C